Validation of 99mTc- EDDA - HYNIC -TOC Kits for Diagnosis of Neuroendocrine Tumors
Phase 2
Completed
- Conditions
- Neuroendocrine Tumors
- Interventions
- Other: 99m Tc - HYNIC -TOC EDDA and 111In - DTPA-octreotide
- Registration Number
- NCT02691078
- Lead Sponsor
- Latin American Cooperative Oncology Group
- Brief Summary
Evaluation of the properties of the image capture test using 99m Tc - HYNIC -TOC EDDA (octreotide labeled with 99mTc) for the diagnosis of neuroendocrine tumors compared to the 111In - DTPA-octreotide.
- Detailed Description
Not available
Recruitment & Eligibility
- Status
- COMPLETED
- Sex
- All
- Target Recruitment
- 15
Inclusion Criteria
- Patients with histological diagnosis of neuroendocrine tumors
- Patients with indication for the staging exam with 11In
- Patients diagnosed in any tumor stage
- Patients with > 18 years
- Male and female patients
- Patients not receiving somatostatin analogues for at least 1 month before image capturing
Exclusion Criteria
- Pregnant women
- Patients with previous tumor resection of the primary tumor without metastatic disease
Study & Design
- Study Type
- INTERVENTIONAL
- Study Design
- SINGLE_GROUP
- Arm && Interventions
Group Intervention Description Adult patients with neuroendocrine tumors 99m Tc - HYNIC -TOC EDDA and 111In - DTPA-octreotide -
- Primary Outcome Measures
Name Time Method Analysis of the images captured with 99m Tc - HYNIC -TOC EDDA ( octreotide labeled with 99mTc ) and 111In - DTPA-octreotide for the diagnosis of neurocrine tumors Up to 30 days
- Secondary Outcome Measures
Name Time Method Visualization of the ocurrence of the neuroendocrine tumor lesions with both radiopharmaceutical agents Up to 30 days Number of neuroendocrine tumor lesions visualized with both radiopharmaceutical agents Up to 30 days
Trial Locations
- Locations (1)
Instituto do Cérebro do Rio Grande do Sul
🇧🇷Porto Alegre, Rio Grande Do Sul, Brazil